(Q50626949)

English

Phase II study of acivicin in patients with recurrent high grade astrocytoma.

scientific article published in January 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Phase II study of acivicin in patients with recurrent high grade astrocytoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

author name string

Olver IN

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Green M

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Millward MJ

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Bishop JF

4

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Journal of Clinical Neuroscience

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

5

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

46-48

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Acivicin: a new glutamine antagonist in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I evaluation of AT-125 single dose every three weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of acivicin in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2898%2990201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0967-5868(98)90201-6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/18644287

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50626949&oldid=1413348966"